Skip Navigation

Advertise|Press|Contact|FAQ|CWConnect

Bookmark/Print/Share

Home » Clinical Trials » Search Clinical Trials
Therapeutic Areas: Oncology | Hematology

Myelodysplastic Syndromes (MDS) Clinical Trials

A listing of Myelodysplastic Syndromes (MDS) medical research trials actively recruiting patient volunteers. Use the filters below to narrow your search results.

Filter by:

Phase:

Gender:

Age:

Location:

 

First 1 2 3 4 Last 

Alabama

Research Site
Mobile Alabama 36608

Phase 2 Study Adding Pracinostat to a Hypomethylating Agent (HMA) in Patients with MDS Who Failed to Respond to Single Agent HMA

California

Alta Bates Comprehensive Cancer Center
Berkeley California 94704

A Phase 3, Multicenter, Randomized, Double-Blind study to compare the efficacy and safety to oral azacitidine plus best supportive care versus placebo plus best supportive care in subjects with low red blood cells requiring transfusions and low platelets due to IPSS lower-risk Myledoysplastic Syndromes (MDS).

California Cancer Associates for Research and Excellence (cCARE)
Escondido California 92025

A Phase 3, Multicenter, Randomized, Double-Blind study to compare the efficacy and safety to oral azacitidine plus best supportive care versus placebo plus best supportive care in subjects with low red blood cells requiring transfusions and low platelets due to IPSS lower-risk Myledoysplastic Syndromes (MDS).

Marin Oncology Associates
Greenbrae California 94904-2007

A Phase 3, Multicenter, Randomized, Double-Blind study to compare the efficacy and safety to oral azacitidine plus best supportive care versus placebo plus best supportive care in subjects with low red blood cells requiring transfusions and low platelets due to IPSS lower-risk Myledoysplastic Syndromes (MDS).

UCSD-Thornton Hospital
La Jolla California 44106-5000

A Phase 3, Multicenter, Randomized, Double-Blind study to compare the efficacy and safety to oral azacitidine plus best supportive care versus placebo plus best supportive care in subjects with low red blood cells requiring transfusions and low platelets due to IPSS lower-risk Myledoysplastic Syndromes (MDS).

Research Site
Los Angeles California 90033

Phase 2 Study Adding Pracinostat to a Hypomethylating Agent (HMA) in Patients with MDS Who Failed to Respond to Single Agent HMA

Colorado

Research Site
Denver Colorado 80218

Phase 2 Study Adding Pracinostat to a Hypomethylating Agent (HMA) in Patients with MDS Who Failed to Respond to Single Agent HMA

View More ▼

Denver Colorado 80218

Patients are needed to participate in a clinical research study evaluating Sotatercept 0.1 mg/kg, Sotatercept 0.3 mg/kg and Sotatercept 0.5 mg/kg for the treatment of Anemia, Myelodysplastic Syndromes (MDS), Chronic Myelomonocytic Leukemia (CMML) or Low to Intermediate-1 MDS

Florida

Research Site
Fort Myers Florida 33916

Phase 2 Study Adding Pracinostat to a Hypomethylating Agent (HMA) in Patients with MDS Who Failed to Respond to Single Agent HMA

Research Site
St. Petersburg Florida 33705

Phase 2 Study Adding Pracinostat to a Hypomethylating Agent (HMA) in Patients with MDS Who Failed to Respond to Single Agent HMA

View More ▼

Tampa Florida 33602

Patients are needed to participate in a clinical research study evaluating Sotatercept 0.1 mg/kg, Sotatercept 0.3 mg/kg and Sotatercept 0.5 mg/kg for the treatment of Anemia, Myelodysplastic Syndromes (MDS), Chronic Myelomonocytic Leukemia (CMML) or Low to Intermediate-1 MDS

Georgia

Phoebe Cancer Center of Phoebe Putney Memorial Hospital
Albany Georgia 31701

A Phase 3, Multicenter, Randomized, Double-Blind study to compare the efficacy and safety to oral azacitidine plus best supportive care versus placebo plus best supportive care in subjects with low red blood cells requiring transfusions and low platelets due to IPSS lower-risk Myledoysplastic Syndromes (MDS).

Illinois

University of Chicago Medical Center
Chicago Illinois 60637

A Phase 3, Multicenter, Randomized, Double-Blind study to compare the efficacy and safety to oral azacitidine plus best supportive care versus placebo plus best supportive care in subjects with low red blood cells requiring transfusions and low platelets due to IPSS lower-risk Myledoysplastic Syndromes (MDS).

Robert H Lurie Comprehensive Cancer Center/ NW Univ
Chicago Illinois 60611

A Phase 3, Multicenter, Randomized, Double-Blind study to compare the efficacy and safety to oral azacitidine plus best supportive care versus placebo plus best supportive care in subjects with low red blood cells requiring transfusions and low platelets due to IPSS lower-risk Myledoysplastic Syndromes (MDS).

Research Site
Chicago Illinois 60601

Phase 2 Study Adding Pracinostat to a Hypomethylating Agent (HMA) in Patients with MDS Who Failed to Respond to Single Agent HMA

Louisiana

Hematology and Oncology Specialists, LLC
Metairie Louisiana 70006

A Phase 3, Multicenter, Randomized, Double-Blind study to compare the efficacy and safety to oral azacitidine plus best supportive care versus placebo plus best supportive care in subjects with low red blood cells requiring transfusions and low platelets due to IPSS lower-risk Myledoysplastic Syndromes (MDS).

Maryland

Baltimore Maryland 21231

Patients are needed to participate in a clinical research study evaluating Sotatercept 0.1 mg/kg, Sotatercept 0.3 mg/kg and Sotatercept 0.5 mg/kg for the treatment of Anemia, Myelodysplastic Syndromes (MDS), Chronic Myelomonocytic Leukemia (CMML) or Low to Intermediate-1 MDS

Massachusetts

UMASS Memorial Hospital
Worcester Massachusetts 1655

A Phase 3, Multicenter, Randomized, Double-Blind study to compare the efficacy and safety to oral azacitidine plus best supportive care versus placebo plus best supportive care in subjects with low red blood cells requiring transfusions and low platelets due to IPSS lower-risk Myledoysplastic Syndromes (MDS).

View More ▼

Boston Massachusetts 02215

Patients are needed to participate in a clinical research study evaluating Sotatercept 0.1 mg/kg, Sotatercept 0.3 mg/kg and Sotatercept 0.5 mg/kg for the treatment of Anemia, Myelodysplastic Syndromes (MDS), Chronic Myelomonocytic Leukemia (CMML) or Low to Intermediate-1 MDS

Minnesota

Mayo Clinic - Rochester
Rochester Minnesota 55905

A Phase 3, Multicenter, Randomized, Double-Blind study to compare the efficacy and safety to oral azacitidine plus best supportive care versus placebo plus best supportive care in subjects with low red blood cells requiring transfusions and low platelets due to IPSS lower-risk Myledoysplastic Syndromes (MDS).

Mississippi

Jackson Oncology Associates PLLC
Jackson Mississippi 39202

A Phase 3, Multicenter, Randomized, Double-Blind study to compare the efficacy and safety to oral azacitidine plus best supportive care versus placebo plus best supportive care in subjects with low red blood cells requiring transfusions and low platelets due to IPSS lower-risk Myledoysplastic Syndromes (MDS).

Missouri

Saint Luke's Cancer Institute
Kansas City Missouri 64111

A Phase 3, Multicenter, Randomized, Double-Blind study to compare the efficacy and safety to oral azacitidine plus best supportive care versus placebo plus best supportive care in subjects with low red blood cells requiring transfusions and low platelets due to IPSS lower-risk Myledoysplastic Syndromes (MDS).

Kansas City VA Medical Center/University of Kansas Medical Center
Kansas City Missouri 64128

A Phase 3, Multicenter, Randomized, Double-Blind study to compare the efficacy and safety to oral azacitidine plus best supportive care versus placebo plus best supportive care in subjects with low red blood cells requiring transfusions and low platelets due to IPSS lower-risk Myledoysplastic Syndromes (MDS).

Nebraska

University of Nebraska Medical Center
Omaha Nebraska 68198-6805

A Phase 3, Multicenter, Randomized, Double-Blind study to compare the efficacy and safety to oral azacitidine plus best supportive care versus placebo plus best supportive care in subjects with low red blood cells requiring transfusions and low platelets due to IPSS lower-risk Myledoysplastic Syndromes (MDS).

New Jersey

Research Site
Hackensak New Jersey 07601

Phase 2 Study Adding Pracinostat to a Hypomethylating Agent (HMA) in Patients with MDS Who Failed to Respond to Single Agent HMA

New York

Mount Sinai Medical Center
New York New York 10029

A Phase 3, Multicenter, Randomized, Double-Blind study to compare the efficacy and safety to oral azacitidine plus best supportive care versus placebo plus best supportive care in subjects with low red blood cells requiring transfusions and low platelets due to IPSS lower-risk Myledoysplastic Syndromes (MDS).

View More ▼

Lake Success New York 11020

Patients are needed to participate in a clinical research study evaluating Sotatercept 0.1 mg/kg, Sotatercept 0.3 mg/kg and Sotatercept 0.5 mg/kg for the treatment of Anemia, Myelodysplastic Syndromes (MDS), Chronic Myelomonocytic Leukemia (CMML) or Low to Intermediate-1 MDS

New York New York 10032

Patients are needed to participate in a clinical research study evaluating Sotatercept 0.1 mg/kg, Sotatercept 0.3 mg/kg and Sotatercept 0.5 mg/kg for the treatment of Anemia, Myelodysplastic Syndromes (MDS), Chronic Myelomonocytic Leukemia (CMML) or Low to Intermediate-1 MDS

North Carolina

Eastern Institute of Medical Sciences
Greenville North Carolina 27834

A Phase 3, Multicenter, Randomized, Double-Blind study to compare the efficacy and safety to oral azacitidine plus best supportive care versus placebo plus best supportive care in subjects with low red blood cells requiring transfusions and low platelets due to IPSS lower-risk Myledoysplastic Syndromes (MDS).

North Dakota

Ohio

Research Site
Cincinnati Ohio 45242

Phase 2 Study Adding Pracinostat to a Hypomethylating Agent (HMA) in Patients with MDS Who Failed to Respond to Single Agent HMA

University Hospitals of Cleveland Case Medical Center
Cleveland Ohio 44106-5000

A Phase 3, Multicenter, Randomized, Double-Blind study to compare the efficacy and safety to oral azacitidine plus best supportive care versus placebo plus best supportive care in subjects with low red blood cells requiring transfusions and low platelets due to IPSS lower-risk Myledoysplastic Syndromes (MDS).

Research Site
Cleveland Ohio 44195

Phase 2 Study Adding Pracinostat to a Hypomethylating Agent (HMA) in Patients with MDS Who Failed to Respond to Single Agent HMA

View More ▼

Cleveland Ohio 44195

Patients are needed to participate in a clinical research study evaluating Sotatercept 0.1 mg/kg, Sotatercept 0.3 mg/kg and Sotatercept 0.5 mg/kg for the treatment of Anemia, Myelodysplastic Syndromes (MDS), Chronic Myelomonocytic Leukemia (CMML) or Low to Intermediate-1 MDS

Oregon

Kaiser Permanente Northwest Oncology/Hematology
Portland Oregon 97227

A Phase 3, Multicenter, Randomized, Double-Blind study to compare the efficacy and safety to oral azacitidine plus best supportive care versus placebo plus best supportive care in subjects with low red blood cells requiring transfusions and low platelets due to IPSS lower-risk Myledoysplastic Syndromes (MDS).

Pennsylvania

University of Pennsylvania
Philadelphia Pennsylvania 19104

A Phase 3, Multicenter, Randomized, Double-Blind study to compare the efficacy and safety to oral azacitidine plus best supportive care versus placebo plus best supportive care in subjects with low red blood cells requiring transfusions and low platelets due to IPSS lower-risk Myledoysplastic Syndromes (MDS).

Tennessee

Research Site
Chattanooga Tennessee 37404

Phase 2 Study Adding Pracinostat to a Hypomethylating Agent (HMA) in Patients with MDS Who Failed to Respond to Single Agent HMA

Research Site
Nashville Tennessee 37203

Phase 2 Study Adding Pracinostat to a Hypomethylating Agent (HMA) in Patients with MDS Who Failed to Respond to Single Agent HMA

View More ▼

Nashville Tennessee 37203

Patients are needed to participate in a clinical research study evaluating Sotatercept 0.1 mg/kg, Sotatercept 0.3 mg/kg and Sotatercept 0.5 mg/kg for the treatment of Anemia, Myelodysplastic Syndromes (MDS), Chronic Myelomonocytic Leukemia (CMML) or Low to Intermediate-1 MDS

Texas

Research Site
Dallas Texas 75246

Phase 2 Study Adding Pracinostat to a Hypomethylating Agent (HMA) in Patients with MDS Who Failed to Respond to Single Agent HMA

Brooke Army Medical Center Francis Street Medical Center
Fort Sam Houston Texas 78235-8200

A Phase 3, Multicenter, Randomized, Double-Blind study to compare the efficacy and safety to oral azacitidine plus best supportive care versus placebo plus best supportive care in subjects with low red blood cells requiring transfusions and low platelets due to IPSS lower-risk Myledoysplastic Syndromes (MDS).

Millenium Oncology
Houston Texas 77090

A Phase 3, Multicenter, Randomized, Double-Blind study to compare the efficacy and safety to oral azacitidine plus best supportive care versus placebo plus best supportive care in subjects with low red blood cells requiring transfusions and low platelets due to IPSS lower-risk Myledoysplastic Syndromes (MDS).

MD Anderson Cancer Center The University of Texas
Houston Texas 77030

A Phase 3, Multicenter, Randomized, Double-Blind study to compare the efficacy and safety to oral azacitidine plus best supportive care versus placebo plus best supportive care in subjects with low red blood cells requiring transfusions and low platelets due to IPSS lower-risk Myledoysplastic Syndromes (MDS).

Michael Debakey VA Medical Center
Houston Texas 77030

A Phase 3, Multicenter, Randomized, Double-Blind study to compare the efficacy and safety to oral azacitidine plus best supportive care versus placebo plus best supportive care in subjects with low red blood cells requiring transfusions and low platelets due to IPSS lower-risk Myledoysplastic Syndromes (MDS).

Research Site
Houston Texas 77030

Phase 2 Study Adding Pracinostat to a Hypomethylating Agent (HMA) in Patients with MDS Who Failed to Respond to Single Agent HMA

Research Site
San Antonio Texas 78229

Phase 2 Study Adding Pracinostat to a Hypomethylating Agent (HMA) in Patients with MDS Who Failed to Respond to Single Agent HMA

View More ▼

Houston Texas 77030

Patients are needed to participate in a clinical research study evaluating Sotatercept 0.1 mg/kg, Sotatercept 0.3 mg/kg and Sotatercept 0.5 mg/kg for the treatment of Anemia, Myelodysplastic Syndromes (MDS), Chronic Myelomonocytic Leukemia (CMML) or Low to Intermediate-1 MDS

Tyler Texas 75702

Patients are needed to participate in a clinical research study evaluating Sotatercept 0.1 mg/kg, Sotatercept 0.3 mg/kg and Sotatercept 0.5 mg/kg for the treatment of Anemia, Myelodysplastic Syndromes (MDS), Chronic Myelomonocytic Leukemia (CMML) or Low to Intermediate-1 MDS

Virginia

VA Commonwealth University Massey Cancer Center
Richmond Virginia 23298-0037

A Phase 3, Multicenter, Randomized, Double-Blind study to compare the efficacy and safety to oral azacitidine plus best supportive care versus placebo plus best supportive care in subjects with low red blood cells requiring transfusions and low platelets due to IPSS lower-risk Myledoysplastic Syndromes (MDS).

View More ▼

Norfolk Virginia 23502

Patients are needed to participate in a clinical research study evaluating Sotatercept 0.1 mg/kg, Sotatercept 0.3 mg/kg and Sotatercept 0.5 mg/kg for the treatment of Anemia, Myelodysplastic Syndromes (MDS), Chronic Myelomonocytic Leukemia (CMML) or Low to Intermediate-1 MDS

First 1 2 3 4 Last 

Receive E-mails About New Clinical Trials!

Sign up for our FREE service and we'll send you automatic email notifications as soon as a clinical trial is posted in the medical category you're interested in.